The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 650-660

  Kapitza, Christoph ^a   Zdravkovic, Milan ^b   Hindsberger, Charlotte ^b   Flint, Anne ^b  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Acetaminophen; Drug interaction; Glucagon like peptide 1; Incretin; Liraglutide; Pharmacokinetics; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; PARACETAMOL; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VITAL SIGN;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; YOUNG ADULT;

EID: 82455213000     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0044-y     Document Type: Article

References (36)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR.Glucagon-like peptide-1 7-36: A physiologicalincretin in man. Lancet. 1987;2:1300-1304.
2. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-likepeptide 1 promotes satiety and suppresses energyintake in humans. J Clin Invest. 1998;101:515-520. (Pubitemid 28084232)
3. Hellström PM. GLP-1 playing the role of agut regulatory compound. Acta Physiol. (Oxf)2010;201;151-156.
4. Edholm T, Degerblad M, Gryback P., et al.Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil.2010;22:1191-1200, e315.
5. Tourrel C, Bailbe D, Lacorne M, Meile MJ,Kergoat M, Portha B. Persistent improvement oftype 2 diabetes in the Goto-Kakizaki rat modelby expansion of the beta-cell mass during theprediabetic period with glucagon-like peptide-1 orexendin-4. Diabetes. 2002;51:1443-1452. (Pubitemid 34826610)
6. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B.Glucagon-like peptide-1 and exendin-4 stimulatebeta-cell neogenesis in streptozotocin- treatednewborn rats resulting in persistently improvedglucose homeostasis at adult age. Diabetes.2001;50:1562-1570. (Pubitemid 33639596)
7. Holst JJ, Deacon CF. Inhibition of the activity ofdipeptidyl-peptidase IV as a treatment for type 2diabetes. Diabetes. 1998;47:1663-1670. (Pubitemid 28476238)
8. Deacon CF, Johnsen AH, Holst JJ. Degradation ofglucagon-like peptide-1 by human plasma in vitroyields an N-terminally truncated peptide thatis a major endogenous metabolite in vivo. J ClinEndocrinol Metab. 1995;80:952-957.
9. Knudsen LB, Agersø H, Bjenning C., et al. GLP-1derivatives as novel compounds for the treatmentof type 2 diabetes: Selection of NN2211 for clinicaldevelopment. Drugs Future. 2001;26:677-685. (Pubitemid 32979149)
10. Agersø H, Jensen LB, Elbrond B, RolanP, Zdravkovic M. The pharmacokinetics,pharmacodynamics, safety and tolerability ofNN2211, a new long-acting GLP-1 derivative, inhealthy men. Diabetologia. 2002;45:195-202. (Pubitemid 34208381)
11. Elbrønd B, Jakobsen G, Larsen S., et al.Pharmacokinetics, pharmacodynamics, safety,and tolerability of a single-dose of NN2211, along-acting glucagon-like peptide 1 derivative,in healthy male subjects. Diabetes Care.2002;25:1398-1404. (Pubitemid 41071152)
12. Knudsen LB, Nielsen PF, Huusfeldt P.O., et al.Potent derivatives of glucagon-like peptide-1 withpharmacokinetic properties suitable for once dailyadministration. J Med Chem. 2000;43:1664-1669. (Pubitemid 30304999)
13. Harder H, Nielsen L, Thi TD, Astrup A. The effectof liraglutide, a long-acting glucagon-like peptide 1derivative, on glycemic control, body composition,and 24-h energy expenditure in patients with type2 diabetes. Diabetes Care. 2004;27:1915-1921. (Pubitemid 38989232)
14. Degn KB, Juhl CB, Sturis J., et al. One week'streatment with the long-acting glucagon-likepeptide 1 derivative liraglutide (NN2211) markedlyimproves 24-h glycemia and alpha- and betacellfunction and reduces endogenous glucoserelease in patients with type 2 diabetes. Diabetes.2004;53: 1187-1194. (Pubitemid 38569002)
15. Zinman B, Gerich J, Buse J., et al. Efficacy and safetyof the human glucagon-like peptide-1 analogliraglutide in combination with metformin andthiazolidinedione in patients with type 2 diabetesmellitus (LEAD-4 Met + TZD). Diabetes Care.2009;32:1224-1230.
16. Russell-Jones D, Vaag A, Schmitz O., et al.Liraglutide vs insulin glargine and placebo incombination with metformin and sulfonylureatherapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial.Diabetologia. 2009;52:2046-2055.
17. Nauck M, Frid A, Hermansen K., et al. Efficacyand safety comparison of liraglutide, glimepiride,and placebo, all in combination with metformin,in type 2 diabetes. The LEAD (Liraglutide Effectand Action in Diabetes)-2 study. Diabetes Care.2009;32:84-90.
18. Marre M, Shaw J, Brändle M., et al. Liraglutide,a once-daily human GLP-1 analogue, added toa sulphonylurea over 26 weeks produces greaterimprovements in glycaemic and weight controlcompared with adding rosiglitazone or placebo insubjects with type 2 diabetes (LEAD-1 SU). DiabetMed. 2009;26:268-278.
19. Garber A, Henry R, Ratner R., et al. Liraglutideversus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono): A randomised, 52-week, phaseIII, double-blind, parallel-treatment trial. Lancet.2009;373:473-481.
20. Buse JB, Rosenstock J, Sesti G., et al. Liraglutideonce a day versus exenatide twice a day for type2 diabetes: A 26-week randomised, parallel-group,multinational, open-label trial (LEAD-6). Lancet.2009;374:39-47.
21. Victoza® (liraglutide [rDNA origin] injection)[product information]. Soeborg, Denmark: NovoNordisk A/S; 2010. Available at: Www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022341lbl.pdf.Accessed May 23, 2011.
22. Willems M, Quartero AO, Numans ME. How usefulis paracetamol absorption as a marker of gastricemptying? A systematic literature study. Dig DisSci. 2001;46:2256-2262. (Pubitemid 32955241)
23. Food and Drug Administration (FDA). Guidancefor Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediatereleasesolid oral dosage forms based on abiopharmaceutics classification system. August2000. Available at: Www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed May 23, 2011.
24. Food and Drug Administration (FDA). Guidancefor Industry: In vivo drug metabolism/drug interaction studies - study design,data analysis and recommendations fordosing and labelling. November 1999.Available at: Www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072119.pdf. Accessed May 23, 2011.
25. The European Agency for the Evaluation ofMedicinal Products. Note for guidance on theinvestigation of drug interactions (CPMP/EWP/560/95). December 1997. Available at: Www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002966.pdf.Accessed May 23, 2011.
26. Blase E, Taylor K, Gao HY, Wintle M, Fineman M.Pharmacokinetics of an oral drug (acetaminophen)administered at various times in relation tosubcutaneous injection of exenatide (exendin-4)in healthy subjects. J Clin Pharmacol. 2005;45:570-577. (Pubitemid 40562948)
27. Greiff JM, Rowbotham D. Pharmacokineticdrug interactions with gastrointestinal motilitymodifying agents. Clin Pharmacokinet.1994;27:447-461. (Pubitemid 24364787)
28. Vilsbøll T, Zdravkovic M, Le-Thi T., et al. Liraglutide,a long-acting human glucagon-like peptide-1analog, given as monotherapy significantlyimproves glycemic control and lowers body weightwithout risk of hypoglycemia in patients with type2 diabetes. Diabetes Care. 2007;30:1608-1610. (Pubitemid 46871185)
29. Jonker D, Toft AD, Kristensen P, Knudsen LB,Watson E. Pharmacokinetic modelling of the once-daily human glucagon-like peptide-1 analogueliraglutide in healthy volunteers and comparisonto exenatide [abstract]. Diabetes. 2007;56(Suppl.1):Abstract 160.
30. Nauck MA, Niedereichholz U, Ettler R, etal. Glucagon-like peptide 1 inhibition ofgastric emptying outweighs its insulinotropiceffects in healthy humans. Am J Physiol.1997;273:E981-E988.
31. Meier JJ, Gallwitz B, Salmen S., et al. Normalizationof glucose concentrations and decelerationof gastric emptying after solid meals duringintravenous glucagon-like peptide 1 in patientswith type 2 diabetes. J Clin Endocrinol Metab.2003;88:2718-2725.
32. Meier JJ, Gethmann A, Götze O., et al. Glucagonlikepeptide 1 abolishes the postprandial rise intriglyceride concentrations and lowers levels ofnon-esterified fatty acids in humans. Diabetologia.2006;49:452-458. (Pubitemid 43277867)
33. Flint A, Kapitza C, Hindsberger C, Zdravkovic M.The once-daily human glucagon-like peptide-1(GLP-1) analog liraglutide improves postprandialglucose levels in type 2 diabetes patients. Adv Ther.2011;28:213-226.
34. Malm-Erjefält M, Ekblom M, Brøndsted L, Vouis J,Lennernäs H, Zdravkovic M. A randomised, doubleblind,cross-over trial investigating the effect ofliraglutide on the absorption pharmacokinetics ofconcomitantly administered oral drugs in healthysubjects [abstract]. Diabetes. 2008;57(Suppl.1):Abstract 130.
35. DeFronzo RA, Okerson T, Viswanathan P, Guan X,Holcombe JH, MacConell L. Effects of exenatideversus sitagliptin on postprandial glucose, insulinand glucagon secretion, gastric emptying, andcaloric intake: A randomized, cross-over study. CurrMed Res Opin. 2008;24:2943-2952.
36. Chang AM, Jakobsen G, Sturis J., et al. The GLP-1derivative NN2211 restores ß-cell sensitivity toglucose in type 2 diabetic patients after a singledose. Diabetes. 2003;52:1786-1791. (Pubitemid 36792471)